308080.KQ ViGenCell Inc.

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
4,655 KRW
Close of Oct 30, 2026
3,070 17,360
Market cap
KRW 95.4B
P/E
-
P/B
2.46x
ROE
-25.4%
Dividend yield
-
Fundamental score
0.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 308080.KQ undervalued?

Graham number

The Graham number of ViGenCell Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ViGenCell Inc. fundamental analysis

4 of 21 checks passed

ROE 0/2

Low return on equity (-25.4%), below 10%.

ROA 0/1

Return on assets (-19.9%) is below the industry median (1.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-9.1%) is below the industry median (1.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (19.1%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 1/2

Cash covers 2.0 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (2.5x) is above the industry median (0.9x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

ViGenCell Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ViGenCell Inc.

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia …

Full company profile